MANGOCEUTICALS, INC. (MGRX): Nasdaq/NYSE listing notice — Mangoceuticals receives Nasdaq deficiency notice for bid price below $1.00

MANGOCEUTICALS, INC.

Received Nasdaq notice on Feb 4, 2026: bid price below $1.00 for 30 consecutive days.
Has 180 calendar days, until August 3, 2026, to regain compliance by closing at $1.00 or more for 10 consecutive business days.
Company will monitor closing bid price and consider available options to regain compliance.
Received notice has no immediate effect on listing or trading of common stock.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

MANGOCEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(b)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A), 5810(b)

Exact text from the filing

February 4, 2026, Mangoceuticals, Inc. (the “Company”) received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price of the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company can regain compliance with the minimum bid price requirement at any time within the 180-calendar day period following receipt of the Nasdaq

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

MANGOCEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-005587

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.